Pediatric migraine: New diagnostic strategies and treatment options

Expert Review of Neurotherapeutics

Volumn 6, Issue 3, 2006, Pages 291-296

  Pakalnis, Ann ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Headache; Migraine; Pediatric; Therapies; Triptans

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYPROHEPTADINE; ETIRACETAM; FLUNARIZINE; HERBACEOUS AGENT; IBUPROFEN; MAGNESIUM OXIDE; NON PRESCRIPTION DRUG; PARACETAMOL; PROPRANOLOL; RIBOFLAVIN; RIZATRIPTAN; SEROTONIN AGONIST; SUMATRIPTAN; TANACETUM PARTHENIUM EXTRACT; TIMOLOL; TOPIRAMATE; TRIPTAN DERIVATIVE; VALPROATE SEMISODIUM; ZOLMITRIPTAN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; AGGRESSION; ANOREXIA; ARTICLE; BEHAVIOR THERAPY; CARDIOTOXICITY; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIAGNOSTIC APPROACH ROUTE; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; IRRITABILITY; LIVER TOXICITY; MEDICINAL PLANT; METABOLIC ACIDOSIS; MIGRAINE; NEPHROLITHIASIS; NEURAL TUBE DEFECT; PARENT COUNSELING; PARESTHESIA; PATIENT CARE PLANNING; PATIENT COUNSELING; PHOTOPHOBIA; POPULATION; PREVALENCE; PSYCHOPHYSIOLOGY; QT PROLONGATION; RELAXATION TRAINING; REPRODUCIBILITY; SEDATION; SIDE EFFECT; SUICIDE ATTEMPT; TANACETUM PARTHENIUM; TASTE DISORDER; TERATOGENICITY; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ANALGESICS; ANTICONVULSANTS; CHILD; HUMANS; MIGRAINE DISORDERS;

EID: 33645876191     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.3.291     Document Type: Article

References (35)

1. Stewart WF, Linet MS, Celantano DD et al. Age and sex-specific incidence rates of migraine with and without visual aura. Am. J. Epidemiol. 34, 1111-1120 (1991).
2. Stewart WF, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. JAMA 267, 64-69 (1992).
3. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8, 1-96 (1988).
4. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. Cephalagia 24(Suppl. 1), 24-36 (2004). •• New classification criteria for headache.
5. Lewis D, Ashwal S, Hershey A et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents. Report of the American Academy of Neurology. Quality Standards Subcommittee of the Child Neurology Society. Neurology 63, 2214-2215 (2004). •• Comments on guidelines for therapy.
6. Pakalnis A, Kring D, Paolicchi J. Parental satisfaction with sumatriptan nasal spray in childhood migraine. J. Child Neurol. 18, 772-775 (2003).
7. Winner P. Pediatric headaches: what's new? Curr. Opin. Neurol. 12, 269-272 (1999).
8. Holden EW, Deichmann MM, Levy JD. Empirically supported treatments in pediatric psychology: recurrent pediatric headache. J. Pediatric Psychol. 24, 91-109 (1999).
9. Hämäläinen ML, Hoppu K, Velkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled crossover study. Neurology 48, 103-107 (1997). • Double-blind, placebo-controlled comparison of over the counters.
10. Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia 25, 124-131 (2005).
11. Winner P, Rothner AD, Saper J et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 16, 989-997 (2000).
12. Ahonen K, Hämäläinen ML, Rantala H Hoppu K. Nasal sumatriptan is effective in the treatment of migraine attaches in children. Neurology 62, 883-887 (2004).
13. Linder SL. Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in the pediatric neurology office practice. Headache 36, 419-422 (1996).
14. Hämäläinen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized, placebo-controlled study. Do children with migraine respond to oral sumatriptan differently than adults? Neurology 48, 1100-1103 (1997).
15. Winner P, Lewis D, Visser WH et al. Rizatriptan 5mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache 42, 49-55 (2002).
16. Linder SL, Dowson AJ. Zolmitriptan provides effective migraine relief in adolescents. Int. J. Clin. Pract. 54, 466-469 (2000).
17. Hershey AD, Winner P, Lewis D, Wasiewski W. Zolmitriptan 5mg nasal spray is effective and well tolerated in the acute treatment of adolescent migraine. Cephalalgia 25, 899 (2005). •• Abstract study with novel protocol design.
18. Wasiewski WW. Preventive therapy in pediatric migraine. J. Ch. Neurol. 16, 71-78 (2001).
19. Olness K, MacDonald JT, Uden DL. Comparison of self-hypnosis and propranolol in the treatment of juvenile classic migraine. Pediatrics 79, 593-597 (1987).
20. Lewis DW, Diamond S, Scott D, Jones V. Prophylactic treatment of pediatric migraine. Headache 44, 230-237 (2004).
21. Hershey AD, Powers SW, Bentti A, deGrauw T. Effectiveness of amitriptyline in the prophylactic management of childhood headache. Headache 40, 539-549 (2000). • Early study with commonly used medication.
22. Leslie L, Newman T, Chesney J, Perrin J. The Food and Drug Administration's deliberations on anti-depressant use in pediatric patients. Pediatrics 116, 195-204 (2005). •• New guideline affecting use of antidepressants in pediatrics.
23. Sorge F, DeSimone R, Marano E et al. Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled crossover study. Cephalalgia 8, 1-6 (1988).
24. Krymchantowski AV, Nobre ME, Moreira P. Low-dose flunarizine for the prevention of migraine in children. Headache 11, 119-121 (2000).
25. Victor S, Ryan SW. Drugs for preventing migraine headaches in children. Cochrane Database of Syst. Rev. 4, CD002761 (2003). • Excellent review of data in pediatric migraine prevention.
26. Caruso JM, Brown WD, Exil G, Gascon GG. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Headache 40, 672-676 (2000).
27. Pakalnis A, Greenberg G, Drake ME, Paolicchi J. Pediatric migraine prophylaxis with divalproex. J. Child Neurol. 16, 731-734 (2001).
28. Hershey AD, Powers SW, Vockel AL et al. Effectiveness of topiramate in the prevention of childhood headache. Headache 42, 810-818 (2003).
29. Winner P, Pearlman E, Linder S et al. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 45, 1304-1312 (2005). • Recent paper with a large, multicenter study.
30. Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache 44, 238-243 (2004).
31. Wang F, VanDen Eeden SK, Ackerson LM et al. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 43, 601-610 (2003).
32. Vogler BK, Pittler MH, Ernst E. Fever few as a preventive treatment for migraine: a systematic review. Cephalalgia 18, 704-708 (1998).
33. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology 50, 466-470 (1998).
34. Lipton RB, Göbel H, Einhaupl KM et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 63, 2240-2244 (2004).
35. Bigal ME, Lipton RB, Tepper SJ et al. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology 63, 843-847 (2004).